Compare TNF Inhibitors

1 product »

close Created with Sketch.

Humira

AbbVie Inc.

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of non-infectious intermediate, posterior and panuveitis (UV) in adults, among other uses.

At-a-Glance

Mechanism of Action: Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
Dosage: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Adalimumab

Application

Subcutaneous injection

Status

Prescription

Strength

Formulation dependent

Company Information

Contact the company for additional information, availability, or pricing:

AbbVie Inc.

abbvie.com

1 N. Waukegan Road

North Chicago, IL